Iota-carrageenan for COVID-19
Iota-carrageenan for COVID-19
Highlights- Iota-carrageenan reduces risk with low confidence for cases.
- Real-time updates and corrections with a consistent protocol for 227 treatments. Outcome specific analysis and combined evidence from all studies including treatment delay, a primary confounding factor.
Iota-carrageenan COVID-19 studies (1 unreported RCT)
Iota-carrageenan for COVID-19: meta-analysis results
Random-effects meta-analysis. Relative risk with 95% CI. * p < 0.05, ** p < 0.01, *** p < 0.001.
Iota-carrageenan COVID-19 studies (1 unreported RCT)
Iota-carrageenan COVID-19 case results
Iota-carrageenan COVID-19 studies (1 unreported RCT)
Media bias for low-cost COVID‑19 treatments
Media covered only 0.8% of studies showing significantly lower COVID-19 risk
Only 5 positive studies were covered
one each: budesonide, cannabidiol, fluvoxamine, HCQ, vitamin D
34 negative studies were covered
HCQ 12, ivermectin 6, lopinavir/ritonavir 4, azithromycin 3, vitamin D 3, fluvoxamine 2, one each: ibuprofen, metformin, vitamin C, zinc
Media was 3.8× more likely to cover positive studies
19 positive studies were covered
paxlovid 5, remdesivir 3, casirivimab/imdevimab 2, convalescent plasma 2, molnupiravir 2, one each: antiandrogens, peginterferon lambda, sargramostim, tixagevimab/cilgavimab, tocilizumab
Only 6 negative studies were covered
remdesivir 3, one each: bamlanivimab/etesevimab, bebtelovimab, sotrovimab
National treatment protocols
Protocols varied widely
Most widely used early treatments selected by the most populous countries. Official protocols varied widely. Treatments only expected to be helpful for late-stage patients are excluded. low-cost, high-profit, and increased risk.
Full matrix and analysis →| Evidence | Official Acknowledgment | Approx. Delay | |
|---|---|---|---|
| Citrus Fruit (vitamin C) for Scurvy (effectiveness) | 1747: James Lind conducted one of the first-ever controlled clinical trials, proving that oranges and lemons cured scurvy in sailors. | 1795: The British Royal Navy finally made a daily ration of lemon juice a standard issue for all its sailors, effectively eliminating the disease. | 48 years |
| Handwashing (lower mortality) | 1847: Dr. Ignaz Semmelweis provided conclusive proof that having doctors wash their hands with a chlorine solution before delivering babies reduced maternal mortality rates from over 18% to around 1%. | ~1870s: Semmelweis's findings were rejected and he was ridiculed. His work was only validated decades later (after his death). | ~20+ years |
| Helicobacter pylori (bacteria causes ulcers) | 1982-1984: Marshall and Warren discovered that Helicobacter pylori bacteria causes ulcers, confirmed via direct exposure. Officials maintained that ulcers were caused by stress and spicy food. | 1994: The US NIH released a consensus statement officially recommending antibiotics as the standard treatment for peptic ulcers, overturning decades of acid-suppression therapy. | ~12 years |
| Asbestos (causes asbestosis & cancer) | 1924: The British Medical Journal published the first case study of a death from "asbestosis." By 1918, U.S. insurance companies had stopped selling life insurance to asbestos workers. | 1971 (US): The Occupational Safety and Health Administration (OSHA) was formed and began regulating asbestos as a carcinogen, setting the first federal workplace safety standards for it. | ~47 years |
| Leaded Gasoline (neurotoxicity) | ~1924: Dangers of low-level lead exposure were known. Experts like Alice Hamilton warned the U.S. Surgeon General that adding lead to gasoline would cause widespread public poisoning. | 1973 (US): The Environmental Protection Agency (EPA) ordered the first phasedown of lead in gasoline, following the Clean Air Act of 1970. A full ban for on-road vehicles took effect in 1996. | ~49 years |
| Harms of Smoking (causes lung cancer) | 1939: Franz Müller (Germany) published the first case-control epidemiological study strongly linking tobacco smoking to lung cancer. This was followed by major U.S. & U.K. studies in the 1950s. | 1964 (US): The U.S. Surgeon General's report, "Smoking and Health," was released. It was the first U.S. government report to definitively link smoking to lung cancer and heart disease. | 25 years |
Early treatment is more effective: baloxavir marboxil
| Administration | Improvement | Studies |
|---|---|---|
| Nasal & oral | 88% [72‑95%] | 10 |
| Nasal spray/rinse | 59% [50‑66%] | 21 |
| Oral spray/rinse | 38% [25‑49%] | 11 |
| Virucidal action | Chemically inactivating or destroying the structure of viral particles |
| Blocking attachment | Binding to the virus or host cells to prevent viral attachment to host cells |
| Physical barrier | Forming a physical layer over the nasal mucosa preventing viral access to host cells |
| Physical removal | Mechanical washout/flushing of viral particles and mucus (e.g., large volume irrigation) |
| Mucociliary clearance | Stimulating the natural beating of nasal cilia to accelerate the clearing of trapped pathogens |
| Treatment | Mechanisms | Notes |
|---|---|---|
| Azelastine119 |
Antiviral: inhibits interaction between spike protein and ACE2 Antiviral: potential inhibition of viral protease (Mpro) Other: H1-receptor antagonist (antihistamine) Other: mast cell stabilizer |
Antihistamine. Designed to affect human receptors. Risks include dysgeusia, drowsiness, and nasal burning. |
| Cetylpyridinium Chloride120 |
Virucidal: disrupts viral lipid envelope Antiseptic: quaternary ammonium compound |
Chemical virucide. Common in mouthwashes. Can cause temporary staining of teeth or tongue irritation if used frequently. |
| Chlorhexidine121 |
Virucidal: disrupts viral lipid membranes Antiseptic: cationic polybiguanide |
Chemical virucide. May cause tooth staining and altered taste. |
| Chlorpheniramine122 |
Antiviral: binds to viral spike protein to block entry Antiviral: high affinity for viral transport proteins Other: H1-receptor antagonist (1st generation antihistamine) Other: anticholinergic activity |
Antihistamine. Stronger systemic risks than azelastine. Known to cause significant sedation/drowsiness and cognitive impairment. |
| Hydrogen Peroxide123 |
Virucidal: oxidizing agent that destroys viral parts Other: tissue debridement |
Chemical virucide. Can be toxic to healthy tissue if concentration is too high (>1%). Long-term safety on nasal mucosa is debated. |
| Hypochlorous Acid124 |
Virucidal: oxidizes viral proteins, causing aggregation and loss of function. Impairs spike-ACE2 binding Antiseptic: broad-spectrum antimicrobial activity via oxidative damage to microbial proteins and membranes |
Chemical virucide. Activity depends on concentration, pH, and contact time. Saliva may reduce activity. |
| Inhaled Heparin125 |
Antiviral: acts as a decoy receptor (mimics heparan sulfate) Antiviral: anti-inflammatory effects on lung tissue Other: Anticoagulant |
Anticoagulant. Use requires caution regarding bleeding risks. |
| Iota-carrageenan |
Barrier: forms a viscous physical layer on mucosa Trap: electrostatistically traps virus particles (mimics cell surface) |
Physical barrier. High safety profile for daily use. |
| NaCl126 |
Cleaning: physically washes away viral particles Support: moisturizes mucosa to support natural immune barrier |
Physical wash. High degree of safety, reduces viral load via physical removal. |
| Nitric Oxide127 |
Virucidal: physically damages viral structure via nitrosylation Other: vasodilator (relaxes blood vessels) in systemic use |
Virucide/drug hybrid. In nasal spray form, it acts primarily as a topical disinfectant. Rapidly cleared, so systemic vasodilation risks are low but present. |
| Phthalocyanine128 |
Virucidal: generates reactive oxygen species (ROS) when exposed to light to kill virus Other: photosensitizer |
Chemical virucide. A synthetic compound often used in photodynamic therapy. Works by creating an oxidative environment hostile to the virus. |
| Povidone-Iodine129 |
Virucidal: oxidizes viral proteins and destabilizes membrane structures Antiseptic: broad-spectrum bacterial/fungal killer |
Chemical virucide. Highly effective but risk of thyroid absorption with chronic use. Can be irritating to mucous membranes. |
| Sodium Bicarbonate130 |
Environment: raises pH to inhibit viral fusion Cleaning: improves mucociliary clearance (washing) |
Physical/chemical environment. Changes the environment rather than attacking the virus directly. High degree of safety. |
| Treatment | Microbiome disruption potential | Notes |
|---|---|---|
| Iota-carrageenan | Low | Primarily antiviral, however extended use may mildly affect the microbiome |
| Nitric Oxide127 | Low to moderate | More selective towards pathogens, however excessive concentrations or prolonged use may disrupt the balance of bacteria |
| Alkalinization133 | Moderate | Increases pH, negatively impacting beneficial microbes that thrive in a slightly acidic environment |
| Cetylpyridinium Chloride120 | Moderate | Quaternary ammonium broad-spectrum antiseptic that can disrupt beneficial and harmful bacteria |
| Hypochlorous Acid124 | Moderate | Broad-spectrum oxidizing antiseptic that may affect beneficial and harmful bacteria |
| Phthalocyanine128 | Moderate to high | Photodynamic compound with antimicrobial activity, likely to affect the microbiome |
| Chlorhexidine121 | High | Potent antiseptic with broad activity, significantly disrupts the microbiome |
| Hydrogen Peroxide123 | High | Strong oxidizer, harming both beneficial and harmful microbes |
| Povidone-Iodine129 | High | Potent broad-spectrum antiseptic harmful to beneficial microbes |
reduces riskIota-carrageenan
increases risk →

| Carvallo (B), 11/17/2020, prospective, Argentina, peer-reviewed, 4 authors, this trial uses multiple treatments in the treatment arm (combined with ivermectin) - results of individual treatments may vary, excluded: combined treatment may significantly contribute to efficacy, concern about potential data issues. | risk of case, 99.9% lower, RR 0.001, p < 0.001, treatment 0 of 788 (0.0%), control 237 of 407 (58.2%), NNT 1.7, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm). |
| Carvallo (C), 10/19/2020, prospective, Argentina, preprint, 1 author, this trial uses multiple treatments in the treatment arm (combined with ivermectin) - results of individual treatments may vary, trial NCT04425850 (history), excluded: combined treatment may significantly contribute to efficacy, concern about potential data issues. | risk of case, 96.3% lower, RR 0.04, p < 0.001, treatment 0 of 131 (0.0%), control 11 of 98 (11.2%), NNT 8.9, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm). |
| Figueroa, 4/15/2021, Double Blind Randomized Controlled Trial, Argentina, peer-reviewed, 18 authors, study period 24 July, 2020 - 20 December, 2020, trial NCT04521322 (history) (CARR-COV-02). | risk of symptomatic case, 80.2% lower, RR 0.20, p = 0.03, treatment 2 of 196 (1.0%), control 10 of 198 (5.1%), NNT 25, odds ratio converted to relative risk. | Jessop, 11/18/2022, Double Blind Randomized Controlled Trial, placebo-controlled, United Kingdom, trial NCT04590365 (history) (ICE-COVID). | 480 patient RCT with results unknown and over 4 years late. |


